Ultragenyx Pharmaceutical (UP0) Price & Analysis

2 Followers

UP0 Stock Chart & Stats

€21.53

-€0.38(-1.59%)

At close: Jul 24 4:00 PM EDT

€21.53

-€0.38(-1.59%)

Day’s Range― - ―

52-Week Range€12.80 - €34.00

Previous CloseN/A

Volume0.00

Average Volume (3M)12.00

Market Cap

€1.30B

Enterprise Value€4.31K

Total Cash (Recent Filing)€292.00M

Total Debt (Recent Filing)€1.20B

Price to Earnings (P/E)―

Beta0.87

Next Earnings

Nov 04, 2026

EPS Estimate

-0.75

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-5.84

Shares Outstanding98,588,875

10 Day Avg. Volume37

30 Day Avg. Volume12

Financial Highlights & Ratios

PEG Ratio0.54

Price to Book (P/B)-28.35

Price to Sales (P/S)3.37

P/FCF Ratio-4.80

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€23.66

Price Target Upside9.88% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering20

EPS Forecast (FY)-3.45

Revenue Forecast (FY)€647.29M

Bulls Say, Bears Say

Bulls Say

Revenue Growth And High Gross MarginsUltragenyx is scaling its commercial base while retaining very high gross profitability, indicating strong economics in its specialty rare-disease products. Continued revenue expansion gives the company a foundation to absorb operating investments and improve future earnings if expenses become more disciplined.

Broad Commercial Portfolio And Geographic ExpansionMultiple marketed therapies and growth across several regions reduce reliance on a single product and demonstrate commercial execution in specialty markets. Evkeeza's 50% year-over-year growth and expanding patient access add a potentially durable contributor to the existing franchise.

GENGLYCOS Accelerated FDA ApprovalThe GENGLYCOS approval expands Ultragenyx's commercial rare-disease platform with a gene therapy addressing an ultra-rare condition. The reported Phase 3 reduction in cornstarch requirements supports launch potential, while long-term follow-up can build additional evidence.

Bears Say

Deep Operating Losses And Persistent Cash BurnUltragenyx's strong gross margins have not yet translated into sustainable profitability because operating costs remain substantially higher than gross profit. Persistent cash consumption can require continued external funding and limits the resources available for pipeline investment.

Negative Equity And Elevated LeverageNegative equity and the reported debt increase materially weaken financial flexibility and raise refinancing risk. A more leveraged balance sheet can constrain capital allocation, make the company more sensitive to execution setbacks, and increase dependence on successful product growth.

Late-stage Pipeline Setback And Clinical UncertaintyThe ASPIRE failure removes support for an important late-stage pipeline opportunity and raises questions about future development productivity in Angelman syndrome. Reassessing the program and cutting expenses may help preserve cash, but also narrows potential long-term growth.

Ultragenyx Pharmaceutical News

Ultragenyx price target lowered to $32 from $43 at Barclays

Barclays analyst Eliana Merle lowered the firm’s price target on Ultragenyx (RARE) to $32 from $43 and keeps...

5d ago

RARE

Ultragenyx downgraded at Morgan Stanley after Angelman study fails

As previously reported, Morgan Stanley downgraded Ultragenyx (RARE) to Equal Weight from Overweight with a price target of...

6d ago

RARE

Ultragenyx downgraded to Equal Weight from Overweight at Morgan Stanley

Morgan Stanley analyst Maxwell Skor downgraded Ultragenyx (RARE) to Equal Weight from Overweight with a price target of...

6d ago

RARE

Ultragenyx falls -44.0%

Ultragenyx (RARE) is down -44.0%, or -$11.67 to $14.86. Published first on TheFly – the ultimate source for...

6d ago

RARE

Midday Fly By: Nvidia to acquire Hugging Face, Broadcom reports Q3 beat

The major averages were sharply higher near noon as Treasury yields pulled back after Federal Reserve Governor Christopher...

6d ago

Ultragenyx falls -44.6%

Ultragenyx (RARE) is down -44.6%, or -$11.83 to $14.70. Published first on TheFly – the ultimate source for...

6d ago

RARE

Ultragenyx downgraded to Neutral from Buy at BofA

BofA downgraded Ultragenyx (RARE) to Neutral from Buy with a price target of $20, down from $48, following...

6d ago

RARE

Broadcom upgraded, Ultragenyx downgraded: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here...

6d ago

AGX

PCG

Why Is Ultragenyx Pharmaceutical Stock (RARE) Down Today?

Ultragenyx Pharmaceutical stock fell over 46% on Thursday following a clinical trial update. ...

6d ago

RARE

Video: Technology in focus following results from Broadcom and HP Enterprise

The Fly has brought its to-the-moment stock market reporting to YouTube! Subscribe if you want to know how...

6d ago

CPB

HPE

Ultragenyx price target lowered to $28 from $77 at Jefferies

Jefferies lowered the firm’s price target on Ultragenyx (RARE) to $28 from $77 and keeps a Buy rating...

6d ago

RARE

Ultragenyx Pharmaceutical (RARE) Stock Jumps 9% on Accelerated FDA Approval

Ultragenyx Pharmaceutical stock rallied 8.99% on Thursday after the FDA granted Ultragenyx Pharmaceutical’s GENGLYCOS accelerated approval. ...

20d ago

RARE

Red Cat, USA Rare Earth, uniQure, Ultragenyx, Copart Trending

Analysts are intrested in these 5 stocks: ( ($RCAT) ), ( ($USAR) ), ( ($QURE) ), ( ($RARE)...

4d ago

CPRT

QURE

Ultragenyx Expands Rare Muscle Pipeline With First-in-Human UX016 Trial in GNE Myopathy

Ultragenyx Pharmaceutical, Inc. ($RARE) announced an update on their ongoing clinical study. The Phase 1/2 study A Phase...

6d ago

RARE

UP0 FAQ

What was Ultragenyx Pharmaceutical’s price range in the past 12 months?

Ultragenyx Pharmaceutical lowest stock price was €12.79 and its highest was €34.00 in the past 12 months.

What is Ultragenyx Pharmaceutical’s market cap?

Ultragenyx Pharmaceutical’s market cap is €1.30B.

When is Ultragenyx Pharmaceutical’s upcoming earnings report date?

Ultragenyx Pharmaceutical’s upcoming earnings report date is Nov 04, 2026 which is in 56 days.

How were Ultragenyx Pharmaceutical’s earnings last quarter?

Ultragenyx Pharmaceutical released its earnings results on Aug 04, 2026. The company reported -€0.777 earnings per share for the quarter, beating the consensus estimate of -€1.051 by €0.274.

Is Ultragenyx Pharmaceutical overvalued?

According to Wall Street analysts Ultragenyx Pharmaceutical’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Ultragenyx Pharmaceutical pay dividends?

Ultragenyx Pharmaceutical does not currently pay dividends.

What is Ultragenyx Pharmaceutical’s EPS estimate?

Ultragenyx Pharmaceutical’s EPS estimate is -0.75.

How many shares outstanding does Ultragenyx Pharmaceutical have?

Ultragenyx Pharmaceutical has 98,588,875 shares outstanding.

What happened to Ultragenyx Pharmaceutical’s price movement after its last earnings report?

Ultragenyx Pharmaceutical reported an EPS of -€0.777 in its last earnings report, beating expectations of -€1.051. Following the earnings report the stock price went up 5.899%.

Which hedge fund is a major shareholder of Ultragenyx Pharmaceutical?

Currently, no hedge funds are holding shares in DE:UP0

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Ultragenyx Pharmaceutical Stock Smart Score

Neutral

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

-3.24%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing innovative treatments for rare and ultra-rare genetic conditions. Its operations span North America, Europe, and other international markets. The company's portfolio of marketed biologic products addresses several serious diseases. This includes Crysvita (burosumab), an antibody that targets fibroblast growth factor 23, used to treat X-linked hypophosphatemia and tumor-induced osteomalacia. Mepsevii offers enzyme replacement therapy for both pediatric and adult patients suffering from Mucopolysaccharidosis VII. Dojolvi is available for individuals with long-chain fatty acid oxidation disorders, while Evkeeza (evinacumab) provides a treatment option for homozygous familial hypercholesterolemia. Ultragenyx also boasts a robust pipeline of investigational therapies. Notable candidates include DTX401, an adeno-associated virus 8 (AAV8) gene therapy for glycogen storage disease type Ia, and DTX301, another AAV8 gene therapy aimed at ornithine transcarbamylase deficiency. Other promising developments feature UX143, a human monoclonal antibody for osteogenesis imperfecta; GTX-102, an antisense oligonucleotide designed for Angelman syndrome; UX701, targeting Wilson disease; and UX053, in development for glycogen storage disease type III. To advance its research and development efforts, Ultragenyx Pharmaceutical Inc. maintains strategic collaboration and licensing agreements with numerous partners, such as Kyowa Kirin Co., Ltd., Saint Louis University, REGENXBIO Inc., Bayer Healthcare LLC, GeneTx, Mereo, University of Pennsylvania, Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc., and Daiichi Sankyo Co., Ltd. The company was founded in 2010 and operates from its headquarters in Novato, California.

Ultragenyx Pharmaceutical (UP0) Earnings & Revenues

Historic Earnings Reports

UP0 Earnings Call

Q2 2026

0:00 / 0:00

Earnings Call Sentiment|Positive

Positive overall: the call highlighted record quarterly revenue, broad-based product growth (including Evkeeza +50% YoY), expanding patient counts across multiple geographies, improving cash consumption versus Q1, and clear near-term catalysts (two PDUFAs and a pivotal readout). Management articulated a credible path to profitability in 2027 with expense discipline and potential non-dilutive PRV monetization. Offsetting risks include a sizable operating loss and expense run-rate, reliance on binary regulatory outcomes, an unmet primary outcome for setrusumab requiring possible new trials, and readout/regulatory uncertainty for GTX-102, but these are framed as manageable and addressable within management's plan.View all DE:UP0 earnings summaries

UP0 Stock 12 Month Forecast

Average Price Target

€23.66

▲(9.88% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"12":"€12","59":"€59","23.75":"€23.8","35.5":"€35.5","47.25":"€47.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":58.55552148,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€58.56</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":23.657880969473684,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€23.66</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":13.77776976,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€13.78</span>\n  </div></div>","useHTML":true}}],"tickPositions":[12,23.75,35.5,47.25,59],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,21.53,24.37811703692308,27.226234073846157,30.074351110769232,32.922468147692314,35.770585184615385,38.61870222153846,41.46681925846154,44.31493629538462,47.1630533323077,50.011170369230776,52.859287406153854,55.707404443076925,{"y":58.55552148,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,21.53,21.693683151497975,21.857366302995953,22.021049454493927,22.184732605991904,22.348415757489878,22.512098908987856,22.67578206048583,22.839465211983807,23.00314836348178,23.16683151497976,23.330514666477733,23.49419781797571,{"y":23.657880969473684,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,21.53,20.933674596923076,20.337349193846155,19.741023790769233,19.14469838769231,18.548372984615384,17.952047581538462,17.35572217846154,16.759396775384616,16.16307137230769,15.56674596923077,14.970420566153846,14.374095163076923,{"y":13.77776976,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":25.6,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.4,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.2,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.6,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.7,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 48,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.5,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.9,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.39,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.37,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.89,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.52,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.53,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >